Go Pro

Fonar (FONR) Competitors

Fonar logo
$19.09 0.00 (0.00%)
As of 06/5/2026

FONR vs. DCTH, SI, CV, ELMD, and SGHT

Should you buy Fonar stock or one of its competitors? MarketBeat compares Fonar with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Fonar include Delcath Systems (DCTH), Shoulder Innovations (SI), CapsoVision (CV), Electromed (ELMD), and Sight Sciences (SGHT). These companies are all part of the "medical equipment" industry.

How does Fonar compare to Delcath Systems?

Delcath Systems (NASDAQ:DCTH) and Fonar (NASDAQ:FONR) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, analyst recommendations, institutional ownership, dividends, valuation and profitability.

61.1% of Delcath Systems shares are held by institutional investors. Comparatively, 50.6% of Fonar shares are held by institutional investors. 19.4% of Delcath Systems shares are held by company insiders. Comparatively, 7.9% of Fonar shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Delcath Systems' average media sentiment score of 0.00 equaled Fonar'saverage media sentiment score.

Company Overall Sentiment
Delcath Systems Neutral
Fonar Neutral

Delcath Systems currently has a consensus price target of $22.50, suggesting a potential upside of 70.45%. Given Delcath Systems' stronger consensus rating and higher possible upside, research analysts plainly believe Delcath Systems is more favorable than Fonar.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Delcath Systems
2 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.43
Fonar
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

Fonar has a net margin of 6.35% compared to Delcath Systems' net margin of 0.62%. Fonar's return on equity of 4.12% beat Delcath Systems' return on equity.

Company Net Margins Return on Equity Return on Assets
Delcath Systems0.62% 0.51% 0.46%
Fonar 6.35%4.12%3.07%

Delcath Systems has a beta of 0.49, indicating that its stock price is 51% less volatile than the broader market. Comparatively, Fonar has a beta of 0.95, indicating that its stock price is 5% less volatile than the broader market.

Fonar has higher revenue and earnings than Delcath Systems. Fonar is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Delcath Systems$85.23M5.35$2.70M$0.011,320.00
Fonar$105.34M1.12$8.33M$1.0019.09

Summary

Delcath Systems and Fonar tied by winning 7 of the 14 factors compared between the two stocks.

How does Fonar compare to Shoulder Innovations?

Shoulder Innovations (NYSE:SI) and Fonar (NASDAQ:FONR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation, media sentiment and analyst recommendations.

50.6% of Fonar shares are owned by institutional investors. 29.0% of Shoulder Innovations shares are owned by company insiders. Comparatively, 7.9% of Fonar shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Shoulder Innovations currently has a consensus target price of $21.00, indicating a potential downside of 0.74%. Given Shoulder Innovations' stronger consensus rating and higher probable upside, research analysts plainly believe Shoulder Innovations is more favorable than Fonar.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Shoulder Innovations
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.57
Fonar
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

Fonar has higher revenue and earnings than Shoulder Innovations. Shoulder Innovations is trading at a lower price-to-earnings ratio than Fonar, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Shoulder Innovations$53.89M8.14-$40.36M-$166.96N/A
Fonar$105.34M1.12$8.33M$1.0019.09

In the previous week, Shoulder Innovations had 2 more articles in the media than Fonar. MarketBeat recorded 2 mentions for Shoulder Innovations and 0 mentions for Fonar. Shoulder Innovations' average media sentiment score of 0.62 beat Fonar's score of 0.00 indicating that Shoulder Innovations is being referred to more favorably in the media.

Company Overall Sentiment
Shoulder Innovations Positive
Fonar Neutral

Fonar has a net margin of 6.35% compared to Shoulder Innovations' net margin of -81.78%. Fonar's return on equity of 4.12% beat Shoulder Innovations' return on equity.

Company Net Margins Return on Equity Return on Assets
Shoulder Innovations-81.78% -35.11% -20.58%
Fonar 6.35%4.12%3.07%

Summary

Fonar beats Shoulder Innovations on 8 of the 15 factors compared between the two stocks.

How does Fonar compare to CapsoVision?

Fonar (NASDAQ:FONR) and CapsoVision (NASDAQ:CV) are both small-cap medical equipment companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, media sentiment, dividends, institutional ownership, analyst recommendations, profitability and earnings.

Fonar has a net margin of 6.35% compared to CapsoVision's net margin of -198.87%. Fonar's return on equity of 4.12% beat CapsoVision's return on equity.

Company Net Margins Return on Equity Return on Assets
Fonar6.35% 4.12% 3.07%
CapsoVision -198.87%N/A -136.03%

CapsoVision has a consensus target price of $8.50, suggesting a potential upside of 16.76%. Given CapsoVision's stronger consensus rating and higher probable upside, analysts plainly believe CapsoVision is more favorable than Fonar.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Fonar
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
CapsoVision
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.50

Fonar has higher revenue and earnings than CapsoVision. CapsoVision is trading at a lower price-to-earnings ratio than Fonar, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fonar$105.34M1.12$8.33M$1.0019.09
CapsoVision$13.56M26.82-$25.32M-$2.34N/A

50.6% of Fonar shares are held by institutional investors. 7.9% of Fonar shares are held by insiders. Comparatively, 2.3% of CapsoVision shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, CapsoVision had 3 more articles in the media than Fonar. MarketBeat recorded 3 mentions for CapsoVision and 0 mentions for Fonar. CapsoVision's average media sentiment score of 0.25 beat Fonar's score of 0.00 indicating that CapsoVision is being referred to more favorably in the news media.

Company Overall Sentiment
Fonar Neutral
CapsoVision Neutral

Summary

Fonar beats CapsoVision on 9 of the 16 factors compared between the two stocks.

How does Fonar compare to Electromed?

Fonar (NASDAQ:FONR) and Electromed (NYSE:ELMD) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, earnings, valuation and risk.

50.6% of Fonar shares are owned by institutional investors. Comparatively, 40.8% of Electromed shares are owned by institutional investors. 7.9% of Fonar shares are owned by company insiders. Comparatively, 10.5% of Electromed shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Fonar's average media sentiment score of 0.00 equaled Electromed'saverage media sentiment score.

Company Overall Sentiment
Fonar Neutral
Electromed Neutral

Fonar has a beta of 0.95, indicating that its share price is 5% less volatile than the broader market. Comparatively, Electromed has a beta of 0.5, indicating that its share price is 50% less volatile than the broader market.

Electromed has a consensus target price of $37.50, indicating a potential downside of 17.46%. Given Electromed's stronger consensus rating and higher possible upside, analysts clearly believe Electromed is more favorable than Fonar.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Fonar
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Electromed
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
3.25

Fonar has higher revenue and earnings than Electromed. Fonar is trading at a lower price-to-earnings ratio than Electromed, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fonar$105.34M1.12$8.33M$1.0019.09
Electromed$71.75M5.24$5.15M$1.1738.83

Electromed has a net margin of 11.34% compared to Fonar's net margin of 6.35%. Electromed's return on equity of 15.71% beat Fonar's return on equity.

Company Net Margins Return on Equity Return on Assets
Fonar6.35% 4.12% 3.07%
Electromed 11.34%15.71%13.37%

Summary

Electromed beats Fonar on 11 of the 15 factors compared between the two stocks.

How does Fonar compare to Sight Sciences?

Fonar (NASDAQ:FONR) and Sight Sciences (NASDAQ:SGHT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, dividends, risk, earnings, media sentiment and valuation.

Fonar has a net margin of 6.35% compared to Sight Sciences' net margin of -46.83%. Fonar's return on equity of 4.12% beat Sight Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Fonar6.35% 4.12% 3.07%
Sight Sciences -46.83%-52.34%-28.49%

50.6% of Fonar shares are held by institutional investors. Comparatively, 55.5% of Sight Sciences shares are held by institutional investors. 7.9% of Fonar shares are held by company insiders. Comparatively, 30.9% of Sight Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Sight Sciences had 1 more articles in the media than Fonar. MarketBeat recorded 1 mentions for Sight Sciences and 0 mentions for Fonar. Fonar's average media sentiment score of 0.00 equaled Sight Sciences'average media sentiment score.

Company Overall Sentiment
Fonar Neutral
Sight Sciences Neutral

Sight Sciences has a consensus target price of $8.14, indicating a potential upside of 49.43%. Given Sight Sciences' stronger consensus rating and higher possible upside, analysts clearly believe Sight Sciences is more favorable than Fonar.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Fonar
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Sight Sciences
1 Sell rating(s)
3 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.44

Fonar has higher revenue and earnings than Sight Sciences. Sight Sciences is trading at a lower price-to-earnings ratio than Fonar, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fonar$105.34M1.12$8.33M$1.0019.09
Sight Sciences$77.36M3.83-$38.43M-$0.71N/A

Fonar has a beta of 0.95, meaning that its stock price is 5% less volatile than the broader market. Comparatively, Sight Sciences has a beta of 2.38, meaning that its stock price is 138% more volatile than the broader market.

Summary

Sight Sciences beats Fonar on 8 of the 15 factors compared between the two stocks.

Get Fonar News Delivered to You Automatically

Sign up to receive the latest news and ratings for FONR and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FONR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

FONR vs. The Competition

MetricFonarMED PRODUCTS IndustryMedical SectorNASDAQ Exchange
Market Cap$117.84M$8.69B$7.16B$12.48B
Dividend YieldN/A2.45%2.66%6.52%
P/E Ratio19.0916.5528.0224.70
Price / Sales1.126.06540.5599.42
Price / Cash9.0918.1149.2657.09
Price / Book0.743.5310.966.46
Net Income$8.33M$226.25M$3.57B$337.01M
7 Day PerformanceN/A1.50%2.12%1.69%
1 Month PerformanceN/A-0.23%5.25%3.81%
1 Year Performance20.79%-0.49%33.29%23.90%

Fonar Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FONR
Fonar
2.3833 of 5 stars
$19.09
flat
N/AN/A$117.84M$105.34M19.09480
DCTH
Delcath Systems
1.6182 of 5 stars
$12.59
-2.8%
$22.50
+78.7%
+3.7%$447.05M$85.23M1,259.0060
SI
Shoulder Innovations
2.2354 of 5 stars
$20.31
-3.7%
$21.00
+3.4%
N/A$437.37M$47.32MN/A61
CV
CapsoVision
1.1367 of 5 stars
$7.58
+0.5%
$8.50
+12.1%
N/A$376.73M$13.55MN/A90
ELMD
Electromed
0.6977 of 5 stars
$42.30
+0.2%
$37.50
-11.3%
+118.6%$350.24M$71.75M56.40160

Related Companies and Tools


This page (NASDAQ:FONR) was last updated on 7/5/2026 by MarketBeat.com Staff.
From Our Partners